PharmAla Biotech Holdings, Inc. (TSE:MDMA)
:MDMA
Want to see TSE:MDMA full AI Analyst Report?
MDMA Stock Chart & Stats
C$0.11
-C$0.03(-8.33%)
At close: 4:00 PM EST
C$0.11
-C$0.03(-8.33%)
Day’s Range― - ―
52-Week RangeC$0.09 - C$0.20
Previous CloseN/A
Volume63.47K
Average Volume (3M)208.17K
Market Cap
C$15.24M
Enterprise ValueC$18.40M
Total Cash (Recent Filing)C$564.71K
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta0.78
Next Earnings
Jul 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding108,887,215
10 Day Avg. Volume94,242
30 Day Avg. Volume208,173
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)5.47
Price to Sales (P/S)22.20
P/FCF Ratio-12.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-Free Balance SheetA zero-debt capital structure provides durable financial flexibility, lowering near-term default risk and preserving borrowing capacity to fund trials or scale manufacturing. Over 2-6 months this supports survival and optionality while the company seeks to improve cash generation.
Revenue Growth TrendSustained TTM revenue growth indicates expanding commercial traction for GMP MDMA products and services. Over the medium term, continued revenue expansion can enable operating leverage, improve unit economics, and reduce reliance on external capital if the company converts scale into positive gross margins.
Strategic Position In Psychedelic TherapeuticsThe company's focus on pharmaceutical‑grade MDMA and regulated supply for clinical trials targets a structurally growing mental‑health therapeutics market. This specialization offers durable demand from trials and future prescription markets, supporting long-term revenue opportunities if regulatory progress continues.
Bears Say
Negative Unit EconomicsNegative gross profit signals that product and manufacturing costs exceed revenues, a structural profitability problem. Unless unit economics are improved through cost reductions, pricing, or scale, the business cannot sustainably cover operating expenses, undermining long-term viability.
Persistent Cash BurnConsistent negative operating and free cash flow means the company relies on external funding to finance operations and trials. Over months this increases dilution risk, limits ability to self‑fund development programs, and constrains strategic options unless cash generation reverses.
Erosion Of Equity ReturnsOngoing net losses erode shareholders' equity and produce negative ROE, which can deplete capital even absent debt. Over a multi‑month horizon this raises the likelihood of recapitalization, asset sales, or partnerships, and weakens the balance sheet's ability to support large clinical investments.
PharmAla Biotech Holdings, Inc. News
MDMA FAQ
What was PharmAla Biotech Holdings, Inc.’s price range in the past 12 months?
PharmAla Biotech Holdings, Inc. lowest stock price was C$0.09 and its highest was C$0.20 in the past 12 months.
What is PharmAla Biotech Holdings, Inc.’s market cap?
PharmAla Biotech Holdings, Inc.’s market cap is C$15.24M.
When is PharmAla Biotech Holdings, Inc.’s upcoming earnings report date?
PharmAla Biotech Holdings, Inc.’s upcoming earnings report date is Jul 24, 2026 which is in 45 days.
How were PharmAla Biotech Holdings, Inc.’s earnings last quarter?
PharmAla Biotech Holdings, Inc. released its earnings results on Apr 21, 2026. The company reported -C$0.003 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.003.
Is PharmAla Biotech Holdings, Inc. overvalued?
According to Wall Street analysts PharmAla Biotech Holdings, Inc.’s price is currently Overvalued.
Does PharmAla Biotech Holdings, Inc. pay dividends?
PharmAla Biotech Holdings, Inc. does not currently pay dividends.
What is PharmAla Biotech Holdings, Inc.’s EPS estimate?
PharmAla Biotech Holdings, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PharmAla Biotech Holdings, Inc. have?
PharmAla Biotech Holdings, Inc. has 108,887,215 shares outstanding.
What happened to PharmAla Biotech Holdings, Inc.’s price movement after its last earnings report?
PharmAla Biotech Holdings, Inc. reported an EPS of -C$0.003 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.226%.
Which hedge fund is a major shareholder of PharmAla Biotech Holdings, Inc.?
Currently, no hedge funds are holding shares in TSE:MDMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PharmAla Biotech Holdings, Inc.
Pharmala Biotech Holdings Inc., operating as PharmAla, concentrates its efforts on the research, manufacturing, and bringing to market of active pharmaceutical ingredients (APIs) within the substituted methylenedioxy-phenethylamine (MDXX) class. The company's offerings further extend to various MDXX class compounds, such as 1,3-Benzodioxolyl-Nmethylbutanamine (MBDB) and 3,4-Methylenedioxy-N-ethylamphetamine (MDEA/MDE), in addition to prepared formulations of these MDXX substances. The enterprise maintains its primary corporate offices in Vancouver, Canada.
Technical Analysis
COSCIENS Biopharma
―
Aptose Biosciences
―
―
PreveCeutical Medical
―
PharmaTher Holdings Ltd
―
Options Prices
Currently, No data available
---